Download PDF
Thromb Haemost 1961; 6(02): 224-234
DOI: 10.1055/s-0038-1654555
Originalarbeiten — Original Articles — Travaux Originaux
Schattauer GmbH

The Formation of Intermediate Product I in a Purified System The Role of Factor IX or of its Precursor and of a Hageman Factor-PTA Fraction

E. T Yin
1   Coagulation Laboratory (Prof. F. Koller) of the Department of Medicine (Prof. P. H. Rossier) Kantonsspital, University of Zürich, Switzerland
,
F Duckert
1   Coagulation Laboratory (Prof. F. Koller) of the Department of Medicine (Prof. P. H. Rossier) Kantonsspital, University of Zürich, Switzerland
› Author Affiliations
Further Information

Publication History

Publication Date:
12 July 2018 (online)

    Permissions and Reprints

Summary

1. The role of two clot promoting fractions isolated from either plasma or serum is studied in a purified system for the generation of intermediate product I in which the serum is replaced by factor X and the investigated fractions.

2. Optimal generation of intermediate product I is possible in the purified system utilizing fractions devoid of factor IX one-stage activity. Prothrombin and thrombin are not necessary in this system.

3. The fraction containing factor IX or its precursor, no measurable activity by the one-stage assay method, controls the yield of intermediate product I. No similar fraction can be isolated from haemophilia B plasma or serum.

4. The Hageman factor — PTA fraction shortens the lag phase of intermediate product I formation and has no influence on the yield. This fraction can also be prepared from haemophilia B plasma or serum.

 

  • References

  • (1) Bachmann F, Duckert F, Fisch U, Streuli F, Gerber D, Koller F. Der Gerinnungsdefekt beim kongenitalen PTA-Mangel. Schweiz. med. Wschr. 88: 1037 1958;
    PubMedGoogle Scholar
  • (2) Bachmann F, Duckert E, Koller F. The Stuart-Prower Factor Assay and Its Clinical Significance. Thromb. Diath. haem. 2: 24 1958;
    PubMedGoogle Scholar
  • (3) Duckert F, Flückiger P, Isenschmid H, Matter M, Vogel-Meng J, Koller F. A Modification of the Thromboplastin Generation Test. Acta haemat. (Basel) 12: 197 1954;
    CrossrefPubMedGoogle Scholar
  • (4) Duckert F, Flückiger P, Matter M, Koller F. Clotting Factor X. Physiologic and Physico-Chemical Properties. Proc. Soc. exp. Biol. (N. Y.) 90: 17 1955;
    CrossrefPubMedGoogle Scholar
  • (5) Duckert F, Loeligeret A, Koller F. Sur un nouveau Facteur de la Coagulation, le Facteur VII. Sa Purification. Helv. chim. Acta 34: 2431 1951;
    CrossrefPubMedGoogle Scholar
  • (6) Duckert F, Yin E. T, Straub W. Separation and Purification of the Blood Clotting Factors by means of Chromatography and Electrophoresis. Preparative methods. Protides of the Biological Fluids. Proc. 8th. Colloquium, Bruges 1960. 41 Elsevier; Amsterdam: 1961
    Google Scholar
  • (7) Fisch U, Duckert F. Some Aspects of Kinetics of the First Stages of Thromboplastin Formation. Thromb. Diath. haem. 3: 98 1959;
    PubMedGoogle Scholar
  • (8) Geiger M, Duckert F, Koller F. Quantitative Bestimmungen von Faktor VIII und IX bei Blutersippen. 413 5th Cong. Europ. Soc. Haemat. Freiburg i. B. 1956. Springer; Heidelberg: 1956
    Google Scholar
  • (9) Koller F, Loeliger A, Duckert F. Experiments on a New Clotting Factor VII. Acta haemat. (Basel) 6: 1 1951;
    CrossrefPubMedGoogle Scholar
  • (10) Yin E. T, Duckert F. Purification of Factor IX or of Its Precursor. Isolation of a Hageman-PTA Fraction. Thromb. Diath. haem. 6: 215 1961;
    PubMedGoogle Scholar